A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBiosense Webster, Inc.

About this trial

The main purpose of this study is to investigate the workflow of the clinical use of the pulsed field (PF) ablation system (VARIPULSE catheter and TRUPULSE generator) when used for cardiac ablation with the new VARIPULSE Pro software in participants with paroxysmal atrial fibrillation (PAF; irregular heartbeat where episodes start and stop on their own, usually within seven days, often resolving within 24-48 hours, though sometimes lasting up to a week) and persistent atrial fibrillation (PsAF; irregular, rapid heartbeat that lasts over 7 days and doesn't stop on its own).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosed with symptomatic persistent atrial fibrillation (PsAF) or paroxysmal atrial fibrillation (PAF)

Selected to undergo an ablation procedure for management of their arrhythmia by pulmonary vein isolation (PVI) only or PVI only with cavotricuspid isthmus (CTI) dependent atrial flutter ablation

Failed at least one antiarrhythmic drug (AAD; class I to IV) as evidenced by recurrent symptomatic atrial fibrillation (AF), or intolerable or contraindicated to the AAD

Age 18-75 years

Disqualifiers

Continuous AF greater than (>) 12 months (1-Year) (Longstanding Persistent AF)

Previous surgical or catheter ablation for atrial fibrillation

Any cardiac surgery within the past 2 months (60 days prior to consent date) (includes percutaneous coronary intervention [PCI])

Previous coronary artery bypass grafting (CABG) in conjunction with valvular surgery, cardiac surgery (for example, ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure

Trial design

Design model

Single group

Treatments tested in this trial

  • Pulsed Field Ablation System

    Device

    Pulsed field ablation by VARIPULSE catheter with TRUPULSE generator along with VARIPULSE pro software will be used.

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: Pulsed Field Ablation: VARIPULSE Catheter with TRUPULSE Generator and VARIPULSE Pro SoftwareExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Total Procedure Time

The total procedure time will be reported.

Time frame
Intraoperative
2

Pulsed Field (PF) Application Time

The PF application time will be reported.

Time frame
Intraoperative
3

Number of PF applications by Pulmonary Vein (PV)

Number of PF applications by PV will be reported.

Time frame
Intraoperative
4

Number of PF applications by Other Cardiac Locations

Number of PF applications by other cardiac locations will be reported.

Time frame
Intraoperative

Secondary outcomes

1

Occurrence of Serious Adverse Device Effects (SADE; Within Seven [7] Days of Index Ablation Procedure) Where the Investigational Devices were Used per Clinical Investigation Plan

A SADE is an adverse device effect that has resulted in any of the consequences characteristic of an serious adverse event (SAE). A SAE is any event that led to any of the following: Death, Serious deterioration in the health of a participant that resulted in any of the following: life-threatening illness or injury, permanent impairment of a body structure or a body function, in-patient hospitalization or prolongation of patient hospitalization, medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function, chronic disease and fetal distress, fetal death or a congenital physical or mental impairment or birth defect.

Time frame
Up to 7 days post index ablation procedure
2

Occurrence of Unanticipated Serious Adverse Device Effects (USADEs)

An USADE is any SAE on health, safety, any life-threatening problem, or death caused by, or associated with a device, if that effect, problem, or death was not previously identified in nature, severity, outcome, or degree of incidence in the current investigational plan or risk analysis report, or any other unanticipated serious problem associated with a device that relates to rights, safety, or welfare of participants.

Time frame
Up to 3 months post index ablation procedure
3

Occurrence of SAEs

An SAE is any event that led to any of the following: Death, Serious deterioration in the health of a participant that resulted in any of the following: life-threatening illness or injury, permanent impairment of a body structure or a body function, in-patient hospitalization or prolongation of patient hospitalization, medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function, chronic disease and fetal distress, fetal death or a congenital physical or mental impairment or birth defect.

Time frame
At 7 days, 8 to 30 days (peri-procedural) and Up to 3 months post index ablation procedure
4

Occurrence of Non-Serious Adverse Events (Non-SAEs)

An Adverse Event (AE) means any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including an abnormal laboratory finding, in participants, users or other persons, in the context of a clinical investigation, whether or not related to the investigational device.

Time frame
Up to 3 months post index ablation procedure

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.